In an asian idiom story, a thief wanted to steal a sledgehammer. But if he broke the bell with the hammer, it would make a loud noise.”Right. I will just cover my ears, so I will not hear anything.Haw-haw, I can’t hear anything now.” Of curse, the thief was caught.
This is also what happens in the treatment of many neurological diseases, such as neuropathic pain. People taking old painkillers may think since the pain was relieved, the neuron damage may be repaired. Just like the thief had his ears plugged, so he think nobody could hear the sound of the bell.
The truth is, for many patients, the neuron continue dying, and keep triggering the alarm of human body as pain, until most painkillers with chronic use become intolerable.
That is the limitation of symptomatic treatment.
The lack of disease modifying treatment has been brought attention in FDA’s public meeting with patients since 2017.
In that meeting, one participant illustrated this concept stating, “I first chose to stop the progression… But once the progression was stopped, I [didn’t] have any pain relief.” Another participant explained that, “… the disease modifying, where all of a sudden you don’t need the pain control, is definitely worth research dollars, of which neuropathy gets very few.”
Our experimental drug, ELB00824, is the next generation of non-opioid painkiller for Neuropathic pain. ELB00824 offers extraordinarily efficacious, highly safe, etiological treatment over currently available low efficacious, symptomatic treatments with narrow therapeutic window. It has the following competitive advantages:
- Providing etiological treatment. Elixiria provides the only disease modifying painkiller, because it targets mitochondria (the important source of neuropathic pain), and PPAR gamma serves as a master gatekeeper in nerve injury and repair.Other painkillers only provide symptomatic treatments, since they only target certain downstream effectors in transduction, or the latter steps in the pain process..
- Extraordinarily efficacious: 100 times more than Pioglitazone, over 30 times more than PEA, over 10 times more than the Carbamazepine, and compatible to gabapentin.
- Highly safe: Non-addictive. Sub-chronical animal study demonstrated that its ingestion is completely safe at the dose of 150 times of effective dose. Topical formulation is used to further improve its safety.